<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386149</url>
  </required_header>
  <id_info>
    <org_study_id>KHNMCOH 2017-08-002</org_study_id>
    <nct_id>NCT03386149</nct_id>
  </id_info>
  <brief_title>Clinical Research on the Efficacy of Bosinji on Herniated Intervertebral Disc of Lumbar Spine</brief_title>
  <official_title>Clinical Research on the Efficacy and Safety of Bosinji on LBP and Radiculopathy by HIVD of L-spine; A Multicenter, Randomized, Controlled, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daegu Korean Medicine Hospital of Daegu Haany University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled clinical trial is designed to evaluate the efficacy and safety of
      Bosinji on low back pain and radiating pain of lumbar herniated intervertebral disc (L-HIVD)
      by assessing pain, function, and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Seventy-four patients between the ages of 19 and 70 with L-HIVD will be recruited by
      eligibility criteria and randomly allocated to the experimental group and the control group.
      In the experimental group, 2.5g of Bosinji granule (Tsumura &amp; Co., Tokyo, Japan) will be
      orally administered three times a day at 30 minutes after the meal for 6 weeks. In the
      control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be
      orally administered in the same usage and period with the experimental group. In addition,
      both group will receive the same acupuncture treatment on 20 acupoints once a week for 6
      weeks. 100 mm visual analogue scale (VAS) for low back pain will be assessed as a primary
      outcome at baseline and treatment end. Also, 100mm VAS for radiating pain, Oswestry
      disability index (ODI), Rolland Morris disability questionnaire (RMDQ), EQ-5D-5L and global
      perceived effect (GPE), Deficiency Syndrome of Kidney Index (DSKI) will be measured as
      secondary outcomes at baseline, 3 weeks after screening, treatment end (6 weeks, primary
      endpoint) and follow-up sessions (10 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline 100mm Pain Visual Analogue Scale (VAS) for low back pain at Week 6</measure>
    <time_frame>Week 0 (Baseline), Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U)</time_frame>
    <description>Measurement instrument for subjective pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>100mm Pain Visual Analogue Scale (VAS) for radiating pain</measure>
    <time_frame>Week 0 (Baseline), Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U)</time_frame>
    <description>Measurement instrument for subjective pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI)</measure>
    <time_frame>Week 0 (Baseline), Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U)</time_frame>
    <description>Validated questionnaire for disability of low back pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol-5 dimensions-5 level (EQ-5D-5L)</measure>
    <time_frame>Week 0 (Baseline), Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U)</time_frame>
    <description>Standardized instrument for generic health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Roland-Morris Disability Questionnaire (RMDQ)</measure>
    <time_frame>Week 0 (Baseline), Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U)</time_frame>
    <description>Health status measure for low back pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Perceived Effect (GPE)</measure>
    <time_frame>Week 3, Week 6 (Primary end point, Treatment end), Week 10 (F/U)</time_frame>
    <description>Assessment of change in the patient's chief complaint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deficiency Syndrome of Kidney Index (DSKI)</measure>
    <time_frame>Week 0 (Baseline), Week 6 (Primary end point, Treatment end)</time_frame>
    <description>Questionnaire for assessing symptoms related to deficiency syndrome of kidney</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Lumbar Disc Herniation</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the experimental group, 2.5g of Bosinji granule (Tsmura Co., Tokyo, Japan) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosinji</intervention_name>
    <description>Product name : Bosinji Granule Manufacturer : Tsumura &amp; Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)
Bosinji extract is composed of following proportion of ingredient
Rehmannia Root 1.7g
Achyranthes Root 1.0g
Cornus Fruit 1.0g
Dioscorea Rhizome 1.0g
Psyllium Husk 1.0g
Alisma Rhizome 1.0g
Hoelen 1.0g
Moutan Root Bark 1.0g
Cinnamon Bark 0.3g
Pulvis Aconiti Tuberis Purificatum 0.3g</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>Ucha-Shinki-Hwan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loxonine tab.</intervention_name>
    <description>Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.
Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)
Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)
Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adults aged 19-70

          2. Radiating pain matched with severer abnormality than bulging shown by CT or MRI on
             lumbar spine

          3. low back pain between 40 and 80 point on 100mm pain visual analogue scale

          4. Volunteers who agree to participate and sign the Informed Consent Form, following a
             detailedexplanation of clinical trials

        Exclusion Criteria:

          1. Congenital abnormalities or surgical history on lumbar regions

          2. Red flag signs that may be suspected of cauda equina syndrome, such as bladder and
             bowel dysfunction or saddle anesthesia

          3. Tumor, fracture or infection in lumbar regions

          4. Injection treatment on lumbar regions within 1 week

          5. Psychiatric disorder currently undergoing treatment such as depression or
             schizophrenia

          6. Liver function abnormality (AST or ALT over 2times normal range)

          7. Renal fuction abnormaility (Serum creatinine &gt; 2.0㎎/㎗)

          8. Other diseases that could affect or interfere with therapeutic outcomes, including
             severe gastrointestinal disease, cardiovascular disease, hypertension, diabetes, renal
             disease, liver disease or thyroid disorder

          9. Contraindication of NSAIDs including intercurrent disease, hypersensitivity reaction
             or other medication

         10. Inappropriate condition for acupuncture due to skin disease or hemostatic disorder (PT
             INR &gt; 2.0 or taking anticoagulant)

         11. Women who is pregnant, breastfeeding or having pregnancy plan

         12. Other inappropriate condition for herbal medicine treatment

         13. participation in other clinical trial with 1 month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-Kwan Seo, PhD., KMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bonhyuk Goo, M.S., KMD</last_name>
    <phone>+821077959940</phone>
    <email>goobh99@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sungjin Kim, M.S., KMD</last_name>
    <phone>+821073398810</phone>
    <email>ksj900716@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongguk University Bundang Oriental Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>13601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eun-Jung Kim, PhD., KMD</last_name>
      <phone>+82317103751</phone>
      <email>hanijjung@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daegu Korean Medicine Hospital of Daegu Haany University</name>
      <address>
        <city>Daegu</city>
        <zip>42158</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I-Rang Choi, B.S</last_name>
      <phone>+82537702324</phone>
      <email>soongood88@dhu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sae-Rom Jeon, B.S.</last_name>
      <phone>+821050478756</phone>
      <email>sr9213@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bonhyuk Goo, M.S., KMD</last_name>
      <phone>+8224406099</phone>
      <email>goobh99@naver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Byung-Kwan Seo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Herniated Intervertebral Disc of Lumbar Spine</keyword>
  <keyword>Low Back Pain</keyword>
  <keyword>Radiculopathy</keyword>
  <keyword>Bosinji</keyword>
  <keyword>Herbal Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiculopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

